Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a report released on Tuesday morning.

Separately, HC Wainwright reissued a neutral rating on shares of Oramed Pharmaceuticals in a report on Monday.

Oramed Pharmaceuticals Stock Down 0.8 %

Oramed Pharmaceuticals stock opened at $2.36 on Tuesday. The firm has a 50 day moving average price of $2.43 and a 200-day moving average price of $2.51. Oramed Pharmaceuticals has a twelve month low of $1.67 and a twelve month high of $3.67. The company has a market capitalization of $95.88 million, a P/E ratio of 9.08 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.21. Equities analysts expect that Oramed Pharmaceuticals will post 0.11 EPS for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals during the 2nd quarter valued at $40,000. Assenagon Asset Management S.A. bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $54,000. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $68,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.